Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Inclusion Criteria: * Be willing and able to provide written informed consent for the trial * Have diagnosis of malignant melanoma. * Be \>= 22 years of age on the day of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 or Karnofsky performance status \>= 70% * Patients must have histological diagnosis of melanoma * Preference is for treatment naive patients that have not gotten previous immunotherapy. However, if approved by principal investigator (PI), patients that have gotten prior PD1 and/or dual immune checkpoint inhibitor therapy may be allowed on this trial if they have progressed intra-cranially or extra-cranially, and have very limited disease progression. * Patient must be asymptomatic at time of getting SRS (day 0) on trial. Prednisone =\< 20 mg/day (4 mg or less of dexamethasone equivalent) for at least 7 days prior to treatment is allowed * Patients with ocular, mucosal and unknown primary melanoma will also be eligible * Patients with 1-10 untreated brain metastases at time of initial brain metastases diagnosis (surgery to at least one of the brain lesions and/or biopsy of a lesion for diagnostic purposes and/or for standard of care purposes is acceptable). If patient has surgical removal of at least one lesion, the investigator would wait for a reasonable time after surgery to start the TTFields, SRS and Immunotherapy. This is typically around 2-4 weeks after resection and clearance by neurosurgery to start t…